close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nurix Therapeutics, Inc. - Common stock (NQ:NRIX)

22.05 -0.30 (-1.34%)
Delayed Quote Updated: 3:34 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Nurix Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 Next >
Nurix Therapeutics (NASDAQ:NRIX) Breakout Setup Backed by Technical Rating of 8 and Setup Rating of 9 ↗
Via Chartmill
News headline image
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell... 
Via Benzinga
Topics Stocks
News headline image
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 ↗
Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies. 
Via The Motley Fool
Nurix Therapeutics Inc (NASDAQ:NRIX) Reports Mixed Q4 2025 Results, Highlights Key Clinical Milestone ↗
Via Chartmill
Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip ↗
Via Stocktwits
News headline image
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
13 Analysts Have This To Say About Nurix Therapeutics ↗
 
Via Benzinga
News headline image
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
News headline image
Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Nurix Therapeutics Posts Downbeat Q3 Results, Joins Orthopediatrics, Levi Strauss And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Applied Digital Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday ↗
US stock futures up, Apogee Enterprises, Levi Strauss, VolitionRX, USANA Health Sciences, Nurix Therapeutics report results. 
Via Benzinga
News headline image
NURIX THERAPEUTICS INC (NASDAQ:NRIX) Misses Q3 2025 Estimates, Shares Drop ↗
Nurix Therapeutics Q3 2025 results miss revenue and EPS estimates, triggering a stock drop. The biotech firm also announced pivotal trial plans for its lead drug candidate. 
Via Chartmill
News headline image
6 Analysts Assess Nurix Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Thursday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts ↗
 
Via Benzinga
News headline image
Amazon To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments ↗
The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout ↗
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib. 
Via Benzinga
News headline image
Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.